​

NRx Pharmaceuticals Stock (NASDAQ:NRXP)

ForecastRevenueOwnershipFinancialsChartTranscripts
NRx Pharmaceuticals by TradingView

Previous Close

$3.15

52W Range

$1.12 - $6.01

50D Avg

$2.98

200D Avg

$2.76

Market Cap

$61.74M

Avg Vol (3M)

$442.17K

Beta

1.74

Div Yield

-

NRXP Company Profile

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

2

IPO Date

Dec 04, 2017

Website

NRXP Performance

NRXP Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-18.50M$-27.59M$-44.40M
Net Income$-25.13M$-30.15M$-35.23M
EBITDA$-18.50M$-30.02M$-39.75M
Basic EPS$-2.39$-3.98$-0.54
Diluted EPS$-2.39$-3.98$-0.54

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q2 25Aug 20, 25 | 8:00 AM
Q1 25May 16, 25 | 4:30 PM
Q4 24Mar 17, 25 | 8:30 AM

Peer Comparison

TickerCompany
OSTXOS Therapies Incorporated
TVRDTvardi Therapeutics, Inc.
CUECue Biopharma, Inc.
OTLKOutlook Therapeutics, Inc.
MNOVMediciNova, Inc.
VERUVeru Inc.
BRNSBarinthus Biotherapeutics plc
ACRVAcrivon Therapeutics, Inc. Common Stock
ALGSAligos Therapeutics, Inc.
RLMDRelmada Therapeutics, Inc.